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Hypophyseal Growth Hormone
II. i n t e r a c t i o n w i t h O t h e r H o r m o n e s

M. Saeed-uz-Zafar, M.D., Raymond C. Mellinger, M.D., and
Lewis B. Morrow, M.D.*
Growth hormone (GH) synthesis and release is ronlrolled by hypothalamic GH
releasing factor. Thyroid hormones, androgens and estrogens in physiologic concentrations enhance GH secretion but a controlling role for glucagon and vasopressin in GH release is not established. Under stress, ACTH directly facilitates
GH release while the similar action of the catecholamines is mediated by the
a-adrenergic receptors. Though physiologic doses of glucorticoids and progestins
do not affect GH liberation, prolonged administration
of
medroxyprogesterone
acetate or of glucocorticoids in high dosage will decrease blood levels or blunt
Gti responsiveness. GH enhances the release of insulin. A shift in adrenal steroid
biosynthesis from the glucocorticoid to the androgenic pathway may also be an
effect of GH administration.
Prolonged elevated GH levels decrease .serum
thyroid binding globulin but increase the turnover of free thyroxine.
Decreased
thyroidal iodine uptake is probably secondary to these changes in thyroxine
metabolism. In hypothyroidism
and severe Cushing's syndrome GH release is
blunted. In most cases of acromegaly as well as in hyperthyroidism
GH is nonsuppressible, while in diabetes its response to stimuli other than hypoglycemia is
exaggerated.

In a previous article' we reviewed
the functions of growth hormone (GH)
as a stimulant to growth and as a factor
regulating intermediary metabolism.
Its secretion is influenced not only by
physical, neuronal and metabolic activity, as previously discussed, but an
important interplay also exists between
GH and other hormones. These hormonal relationships are the subject of
the present discussion.

creted in or around the median eminence. It is transmitted through the
hypothalamic-hypophyseal portal system to the anterior pituitary where it
promotes synthesis and release of GH
by the eosinophilic cells.
Low plasma GH levels and poor response to hypoglycemia have been observed in children with emotional deprivation and growth retardation. GH
response to hypoglycemia became normal after a few days in a supportive
environment and normal growth resumed. Powell et al- believe that deprivation of maternal love in some way
reduces GH secretion in these children.
The situation may be analogous to
anorexia nervosa, in which GH deficiency has also been observed, in
contrast to starvation in which GH
levels are reportedly very high. Pre-

Growth Hormone Releasing
Factor (GHRF)
The synthesis and release of GH is
under the direct influence of a hypothalamic neurohumor, growth hormone
releasing factor (GHRF), which is se'"Division of Endocrinology, Department of
Medicine.
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sumably, alterations in GHRF are responsible for the GH changes characteristic of these clinical states.

lering with its utilization, by increasing
glycogenolysis and by accelerating gluconeogenesis.
Consequent to the rise in glucose
and possibly by direct islet cell stimulation, growth hormone causes synthesis and release of insulin. With prolonged administration, persistently elevated blood sugar may result despite
elevated insulin levels as seen in diabetes of acromegaly.'' Even with normal blood sugar levels, plasma insulin
in acromegalics has been found three
times greater than that of controls.''
Although increased islet cell stimulation secondary to GH effect on the
blood sugar may account for the increased insulin secretion, a markedly
increased insulin secretory capacity
can also be demonstrated, for example,
by tolbutamide testing in acromegalic
patients.'' A similar priming effect on
the beta cells is indicated by the exaggerated insulin response to tolbutamide
administered to dogs treated with GH.'^
This increased secretory reserve correlates with the islet cell hypertrophy
demonstrated in acromegalic subjects
by Recant" as well as in various laboratory animals treated with growth hormone.

Vasopressin
Gagliardino et aP demonstrated a
rise in plasma GH levels after administration of vasopressin to 15 normal
men, women and children. The peak
response occurred 30 minutes after
intramuscular injection. Previously,
others had demonstrated a GH stimulatory effect of lysine-vasopressin in
two normal female subjects but not in
males.* Although vasopressin also stimulates ACTH and TSH release, both
of which are under hypothalamic control, it is unlikely that this polypeptide
plays a physiologic role in anterior
lobe secretory activity.
Corticotrophin (ACTH)
Zahnd et aP recently demonstrated
that 1 mg of synthetic ACTH stimulated GH release in six normal subjects comparable to that which followed insulin-induced hypoglycemia.
The time of peak response ranged from
15 to 90 minutes and the earliest,
highest response occurred in the only
female subject tested. The authors propose that ACTH is a possible mediator
of stress-induced GH release.

The extraordinary insulin secretory
capacity of acromegalic subjects can
also be demonstrated by challenge with
a glucocorticoid (eg, dexamethasone 8
mg/day for 2 days). Under these conditions, normal individuals exhibit a
four- to fivefold increase in plasma
insulin response to tolbutamide. Similar
treatment of acromegalic subjects results in a tenfold increase in plasma
insulin levels.
No significant change in plasma insulin was found by Daughaday and
Kipnis" in normal subjects 30 minutes

Islet Cell Hormones
Although insulin and glucagon both
stimulate GH secretion, the mechanisms of their acdon are somewhat different. Well-known are the opposing
effects of these hormones on the level
of glucose, the primary regulator of
GH secretion. Insulin increases glucose utilization and lowers blood sugar,
stimulating GH secretion. GH, in turn,
tends to raise blood glucose by inter166
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after a single intravenous injection of
5 mg of GH. However, administration
of 10 mg/day for 3-8 days to hypopituitary subjects produced a progressive
increase in both blood sugar and
insulin. Furthermore, carbohydrate tolerance was diminished despite a sixfold increase in plasma insulin response.
On the other hand, plasma GH in
diabetics differs from that of normals
in that diabetics are more sensitive to
GH releasing stimuli other than hypoglycemia. This phenomenon does not
correlate with the presence or absence
of retinopathy.
Recently, Mitchell et aP'^ demonstrated an elevation of plasma GH in
15 individuals within three hours of
the subcutaneous injection of 1 mg of
glucagon. Most often, the peak elevation occurred at two hours and changes
in blood glucose alone could not explain the rise in GH. This observation
is contrary to previous reports that glucagon does not stimulate GH release
but the authors contend that the GH
levels in earlier studies were not observed beyond 90 minutes. The exact
mechanism of glucagon-induced stimulation of GH release is not known but
the late falling glucose levels may contribute or may reflect merely a physiologic fluctuation of GH release.
Corticosteroids
Observations concerning the effects
of glucocorticoids on GH release are
conflicting. The absence of normal
spontaneous GH peaks in two patients
with Cushing's syndrome was demonstrated by Stiel et a l , " but this phenomenon was not reproduced in normal subjects treated with prednisone
15 mg daily. Both Hartog et aP'' and
167

Frantz and Rabkin '" reported that in
adults receiving corticosteroids, GH
response to hypoglycemia is blunted.
Morris et aP' failed to confirm this
claim in children. Our study of growth
hormone in 12 patients with Cushing's
syndrome concludes that the suppression of GH response to hypoglycemia
which occurs in the hypercortical state
is proportional to the duration and
severity of the adrenal hypersecretion.
In these cases, impaired GH release
did not depend upon glucose levels, and
responsiveness was restored with remission of the Cushing's syndrome in
all except one patient who had developed a pituitary tumor. In children
and adolescents with Cushing's syndrome, growth had ceased despite
normal GH response to hypoglycemic
stimulus."" These observations, consistent with the findings in prepubertal
children receiving corticosteroid treatment, suggest that the impaired growth
is the result of steroid-induced antagonism to GH at the tissue level.i* !**
Strauch et al-*^' studied GH releasing
mechanisms in Cushing's syndrome
utilizing insulin, glucose and arginine.
In nine patients who did not respond
to falling glucose, arginine provoked a
GH release in all but three, two of
whom were male. The authors conclude
that this "partial somatotrophin deficiency" in Cushing's syndrome is due
to hypothalamic GHRF inhibition and
that the pituitary GH secretory mechanism is intact. A similar mechanism
may explain the exaggerated GH response in diabetics who also respond
to stimuli other than hypoglycemia.
We have studied GH response to
arginine in four patients with the adrenogenital syndrome, and have evaluated

Table I
EFFECT OF GLUCOCORTICOID THERAPY ON GROWTH HORMONE RESPONSE
TO ARGININE IN ADRENOGENITAL SYNDROME
Growth Hormone mUg/ml
Name

Age o
Sex*

RC

17M

DC

LP

13M

19F

State

0 Min.

30 Min.

45 Min.

60 Min.

Untreated

12.4

15.4

16.8

6.0

TRIAMCINOLONE

15.0

50

17F

80

3.8
53

90 Min.
2.0
20

120 Min. 150 Min.

P'triol
Mq/24-hr

13.6

12.4

32.6

14.5

11.5

0.5

Untreated

1.4

10.0

18.4

12.0

3.4

1.8

7.6

19.8

30.0

TRIAMCINOLONE

6.0

2.0

2.0

2.8

13.2

27.0

21.0

9.7

1.4

Untreated

3.0

44.0

7.0

30.5

PREDNISONE
CC

> 100

75 Min.

14.0

54

30

11.6

74.0

68

54

44

7.8

4.8

2.3

13.4

60

Untreated

2.4

24

> 100

80

> 100

> 100

26.0

10.4

65.0

PREDNISONE

6.8

> 100

> 100

100

> 100

> 100

44.0

9.6

3.3

RC and DC were given triamcinolone and GH response was tested four weeks later. In cases
of LP and CC long-term prednisone treatment was discontinued a month before arginine
stimulation. The higher GH response during treatment is not statistically different from
untreated values. The very high levels in CC are unexplained.

TO
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the effect of glucocorticoid therapy.
Although there was no statistical difference in GH levels, adrenal suppression treatment tended to improve the
GH response (Table I). In one patient
(CC) GH levels were very high after
arginine, and were not affected by corticoid therapy. The somewhat higher
GH levels during corticosteroid administration were unexpected in view
of the tendency of Cortisol to reduce
GH response in other patients. A possible explanation is suggested by the
work of Lawrence and others who have
studied the suppressive effect of medroxyprogesterone acetate on GH release.-' This drug is a methylated derivative of 17-hydroxyprogesterone
which is secreted in high titer by untreated patients with the adrenogenital
syndromes. Urinary pregnanetriol indicates the 17-hydroxyprogesterone
secretion in our patients and the suppressive effect of treatment. Conceivably, this steroid or its metabolites
account for the somewhat lower GH
response observed during the untreated
state. The extraordinary response of
patient CC (Table I), unique to our
experience, is unexplained.

of altering the adrenal response to corticotropin. Rats treated with HGH and
prolactin release less corticosteroid in
response to ACTH than do control
animals.-'' Similarly, basal 17-hydroxycorticoid secretion is reduced in dogs
treated with HGH preparations and
this response is dose-related.-^ In normal human subjects as well as in patients with Cushing's syndrome, GH
reportedly lowers urinary 17-hydroxysteroids.--'^ On the other hand, GH
probably enhances adrenal androgen
secretion, and hirsuitism is a common
clinical finding in acromegalic females.
Reasoning from the characteristic elevation of urinary 17-ketosteroids in
acromegaly, Lim and Dingman-'' postulated GH-induced activation of adrenal
androgenic steroidogenesis. An acromegalic patient has been reported with
non-suppressible adrenal function, virilization, high GH levels, moderately
elevated urinary 17-ketosteroids but
normal 17-hydroxysteroids, presumably the result of excess ACTH secretion in the presence of increased GH.'-"
To evaluate the possible significance
of this GH-adrenal cortex relationship
to growth in childhood, we have studied
adrenal function in eight GH-deficient
children receiving HGH therapy. In
eight-month courses of treatment, a
small reduction in mean 17-hydroxycorticosteroids and Cortisol secretion
rate occurred in these subjects (Table
II), while the urinary androgen metabolites, especially androsterone, increased
(Table III). All children responded to
therapy with accelerated growth.

At the present time there is no
convincing evidence that the corticosteroids normally influence GH release.
Although physiological doses of Cortisol enhance GH production in tissue
cultures of normal human pituitaries as
well as eosinophilic adenomas,-- there
is little doubt that pharmacological
doses of these steroids can impair GH
release and most assuredly antagonize
the growth-promoting effects of the
hormone.
Another subtle relationship may exist
between GH and adrenocortical secretions. GH administration is capable

Catecholamines
A role for epinephrine in the control
of growth hormone secretion is also
unsettled. Blackard and Heidingsfeld169
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Table II

EFFECT OF EXOGENOUS GROWTH HORMONE ON URINARY
17-HYDROXYCORTICOSTEROIDS (17-OHCS) and CORTISOL SECRETION
RATES (CSR) IN 8 DWARF CHILDREN

Sex*^

Before
Treatment

After
Treatment

RK

6M

9.4

4.0

2.4

1.6

DB

5M

12.8

4.7

2.4

3=0

BS

9M

10.3

6.6

2.4

2.7

WR

8M

10.7

6.0

2.0

1.1

GM

12M

5.8

3.9

3.4

1.4

TH

13M

5.6

6.9

2.4

2.7

RKu

15F

4.1

2.6

2.3

1.0

MR

12M

7.6

12.4

12.8

5.7

8.3

5.9

3.8

2.4

Name

Mean

Before
Treatment

After
Treatment

Two mg of human growth hormone three times weekly was administered for eight months.
CSR fell in six of eight subjects and urinary 17-OHCS decreased in five. The mean values
of both CSR and urinary 17-OHCS are lower after treatment but wide variation in the
subjects precludes statistical analysis.

er-^ studied the effect of catecholamines
on plasma GH under conditions of controlled glucose concentration. During
a-adrenergic blockade, insulin-induced
hypoglycemia produced a lesser elevation of growth hormone than that produced without blockade. Conversely,
GH levels were higher with insulininduced hypoglycemia during ^-adre-

nergic blockade, but inhibition of cyclic
3'5-AMP phosphodiesterase activity
with administration of theophylline had
no detectable effect on plasma GH
response. This study is interpreted to
indicate a stimulatory effect by aadrenergic receptors and an inhibitory
effect by /3-adrenergic receptors of
growth hormone secretion, a pattern
170

Table III
EFFECT OF GROWTH HORMONE ON URINARY ANDROGENS
ANDROSTERONE in mg/day

Name
&
Sex

Before
Treatment

RK

6M

.006

DB

5M

BS

ETIOCHOLANOLONE in mg/day

Total 0^902 17- KS in mg/day

After
Treatment

.003

—

.010

.006

.013

.015

.019

.007

.013

.022

.032

9M

.023

.035

.022

.023

.055

WR

8M

.060

.038

.030

.010

.100

.051

GM

I2M

.112

.167

.130

.119

.242

.304

TH

13M

.830

1.161

.290

.274

1.150

1.435

RKu

15F

.030

.031

.008

.040

.039

MR

12M

.400

.689

1.065

1.375

.196

.268

.330

.413

E

Before
Treatment

After
Treatment

Before
Treatment

After
Treatment

o

E
C3
TO
Q)

Mean

HGH was administered 2 mg thrice weekly for eight months. In contrast to reduced Cortisol
secretion, androgen metabolites increased in six of the eight subjects after GH therapy.
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In studies of hyperthyroid patients,
deficient GH release in response to
insulin-induced hypoglycemia was reported by Burgess**^ but others observed
normal responses.*^ On the other hand,
GH suppressibility with glucose is impaired in hyperthyroidism and normal
reactivity returns with restoration to
the euthyroid state. The mechanism of
this resistance is unknown.*^
Limited evidence indicates that GH
may affect binding and transport of the
thyroid hormones. In acromegaly, despite a low or normal free thyroxine
level, an increased thyroxine turnover
rate occurs which may partly explain
the hypermetabolism of the disease.-**
Exogenous administration of GH
slightly decreases the thyroxine binding globulin (TBG) after five days of
administration and low TBG has been
reported in long-standing acromegaly.*-"^
Administration of GH in five-day
courses to normal volunteers also reduced thyroxine binding capacity.*-'
The lower serum thyroxine levels secondary to reduced plasma binding may
be mistakenly interpreted as TSH failure in subjects receiving GH therapy.
Root et al*» studied the effect of HGH
therapy on thyroidal iodine uptake and
serum PBI in 20 children with stunted
growth from various causes. In nine
patients a significant change in uptake
and PBI was observed: in two iodine
uptake increased and PBI increased in
two; in six subjects, both PBI and uptake decreased. The authors interpret
these data as indicating diminished
TSH secretion induced by GH administration. Because exogenous GH has
been shown to lower TBG levels, the
data of Root et al do not permit, in our
opinion, unequivocal interpretation as
direct inhibition of TSH. Conceivably,

opposite to the sympathetic mechanism
controlling the release of insulin. Apparently, catecholamines released during hypoglycemia inhibit insulin secretion and assist in promoting a rise in
GH. The observation that neither adrenergic blockade nor theophylline altered basal GH levels suggests that the
sympathetic nervous system plays no
role in the control of resting GH levels.
However, Imura et aF" earlier demonstrated an elevation of GH after propranolol administration without other
stimulus. Their study also supported
the role of sympathetic receptors in the
control of GH release.
Thyroid
Accelerated growth is a well recognized feature of hyperthyroidism in
childhood-'" while retarded growth is
seen in juvenile myxedema.'i An effect
of thyroid hormone on synthesis and
secretion of GH is suggested by the
decrease in the number of pituitary
acidophils found in patients with myxedema-'- and in rats after thyroidect o m y . j n \)oth children and adults
with primary hypothyroidism GH release is impaired in response either to
insulin-induced hypoglycemia or arResponsiveness returns to
normal after adequate treatment, but
before thyroid therapy the impoverished GH response to hypoglcemia may
suggest an erroneous diagnosis of hypopituitarism. The mechanism by which
thyroid deficiency influences GH synthesis and release may involve GHRF
secretion or GH synthesis and storage
by pituitary cells or both. As stated
previously, adrenergic receptors influence growth hormone secretion, and
thyroxine may exert its effect through
hypothalamic adrenergic receptors.*"
ginine.
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reduced TBG with altered equilibrium
between the free and bound thyroid
hormones accounts both for the lowered PBI and the diminished TSH
effect evidenced by lower iodine uptake. The authors reported TSH assays
only in two patients who were already
hypothyroid. The markedly elevated
levels were somewhat reduced after
five days of GH administration.
Gonadal Steroids
Accelerated growth at puberty, a
universal physiological phenomenon,
suggests the possibility of augmented
growth hormone release in the presence of gonadal steroids. In support of
this hypothesis, Martin et al*^ demonstrated increased GH response to hypoglycemia in a single patient after puberty compared with the prepubertal
values, and in a dwarfed, prepubertal
child they observed enhanced GH release afterfivedays of testosterone administration. Deller and associates**
studied a 12-year-old dwarfed, sexually
infantile male who had negligible GH
response to hypoglycemia. Twenty
hours after a single 400 mg dose of
testosterone, GH response rise to a
similar stimulus was normal and during the next ten weeks the patient grew
5 cm. lUig and Prader*" observed an
improved GH response to hypoglycemia in four patients with anorchia
and one with delayed puberty after two
days of androgen administration. The
response was more pronounced two to
three months after treatment. Although
basal plasma GH levels do not rise at
puberty, the accelerated growth may
well be secondary in part to enhanced
stimulated GH levels.
GH levels during various phases of
the menstrual cycle are comparable,'"
173

but there is evidence for slight increases
during the preovulatory and premenstrual phases. Frantz and Rabkin'^
demonstrated that estrogen administration increases ambulatory GH levels
and Spellacy"- demonstrated similar
effects in patients using the common
combination type oral contraceptives.
Furthermore, the greater GH response
to hypoglycemia which occurs in patients receiving the sequential type of
oral contraceptives is considered to be
due to the estrogen content of the pill.'^
On the other hand, Schwartz^* postulated antagonism between estrogen and
GH at the cellular level, indicated by
their opposite effect on urinary calcium
and hydroxyproline and the serum
phosphorus. That such an antagonism
may be of clinical importance is suggested by our experience with a female
acromegalic patient, age 58, who had
undergone oophorectomy seven years
before diagnosis of her pituitary eosinophilic adenoma. The patient has been
treated with stilbestrol 5 mg daily with
periodic interruptions for a period of
three years. She reports regression of
hand and foot size, shrinking of the
gums and jaws, requiring new dentures,
and relief of headache. GH levels were
somewhat reduced after a month of
treatment but returned to pretreatment
values after six months. (Table IV)
Simon''" demonstrated a blunting of
GH release after hypoglycemia in four
of five men who had received medroxyprogesterone acetate (MPA) 1 gm intramuscular 48 hours previously. Lawrence reported that this synthetic progestin administered orally had similar
effects.-! In 9 of 11 normal volunteers
and 11 of 12 acromegalics receiving
oral MPA, GH response to arginine
was negligible and in 10 acromegalics,
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Table IV

GROWTH HORMONE LEVELS IN A FEMALE ACROMEGALIC
PATIENT RECEIVING STILBESTROL
GH (mug/ml)
2-hr. after glucose

Date

Condition

F

4-14-66

Control

62

62

4- 28-66

Stilbestrol
(5 ml/day)

41

37

5- 27-66

24

7-21-66

48

11-30-66

52

53

9-14-67

59

77

Although there is a decrease in both the fasting and post-glucose GH levels one month after
beginning stilbestrol, GH values are the same as control after 17 months of stilbestrol therapy.
The corresponding blood glucose values were not significantly changed. In all studies 100 gm
of glucose was ingested after the control specimen was obtained. The patient reported
objective improvement in her acromegalic features.

GH levels were strikingly reduced.
Chronic therapy improved the appearance of two. Malaskey and Daughaday'*^
recendy recorded the 24-hour profile of
GH secretion and the response to insulin and arginine infusion in five acromegalics with very high GH levels who
were treated with 40 mgm MPA daily
for six months. During the first two
weeks, GH was elevated in four of five
patients but thereafter levels fell significantly and clinical improvement
occurred. We observed no effect from
MPA given parentally, 100 mg/week
to a post-menopausal female acromegalic subject. Headache seemed to
improve after treatment but neither the
174

basal nor post-glucose GH values were
improved and the blood sugar increased
and hypoglycemic drug therapy was
required. (Table V)
Discussion
The complex functional interrelationships of the hypophyseal polypeptide termed "growth hormone" are
barely implied by this simple designation. Even after growth and maturation
are completed the continuing GH secretion helps to regulate the supply and
utilization of energy substrate while
protecting the integrity of structural
proteins. Throughout life, GH facilitates the incorporation of ingested pro-

Hypophyseal Growth Hormone

Table V
GROWTH HORMONE LEVELS IN AN ACROMEGALIC
TREATED WITH MEDROXYPROGESTERONE ACETATE (MPA)
Date

Condition

GH (mug/ml)

Blood Glucose (mg. %)

F

2-hr.

F

2-hr.

5- 17-69

Control

23

18

90

155

6- 7-69

After MPA

30

22.5

95

230

MPA (200 mgm) was administered intramuscularly in three doses during the two weeks ending
May 31, 1969. The two-hour blood sugar is increased after progestin treatment and GH
values are slightly increased.

contributes to fat deposition in the subcutaneous tissues of the females.
The suppressive effect of pharmacological doses of synthetic progestins
on GH release has no known physiological significance. It may help interpret GH levels in our studies of patients
with congenital adrenal hyperplasia
who had a marked hypersecretion of
17-hydroxyprogesterone in the untreated state. During adrenal suppression by
corticosteroid administration, GH levels were slightly increased.
Corticosteroids in high dosage impair GH release especially after prolonged administration or hypersecretion. To a less striking degree, administered GH may in turn diminish
adrenal Cortisol secretion. A prominent
antagonism exists between GH and
corticosteroids in their cellular effects
and growth of children is markedly
impaired by excess corticoids even
without suppressed GH release. The

teins and amino acids into body tissues.
These two broad areas of function,
mobilization of energy substrate and
maintenance of tissue, are represented
by the two prominent GH release
mechanisms, glucose deficiency and
amino acid plethora.
The manifold interactions between
GH and other hormones may also be
interpreted in terms of regulating
growth, preserving body structural integrity and providing readily accessible
energy stores. In this regard, enhanced
GH response to stimulation observed
in the presence of androgens and estrogens may contribute to the accelerated
growth of adolescence. Moreover, the
synergistic anabolic activity of GH and
androgens undoubtedly promotes pubertal growth. The observed peripheral
antagonism between GH and estrogens
is less clearly of utility to the body
economy. It is possible that peripheral
antagonism between GH and estrogens
175
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adrenal function studies in our GHdeficient children receiving physiologic
doses of HGH also indicated a slight
reduction of Cortisol secretion, an effect
which theoretically enhances the
growth-promoting action of the administered hormone. At the same time,
and very likely as a concomitant of the
lowered Cortisol secretion, urinary androgen metabolites increased. Adrenal
androgen secretion normally increases
progressively and disproportionately in
the growing child, a phenomenon
termed "adrenarche," and the androgen undoubtedly promotes the accelerating late childhood growth. That
GH contributes to the adrenarche
through its influence on adrenocortical
secretion of corticoids and androgens
seems a permissible speculation.
Insulin-deficient children do not
grow normally even in the presence of
GH and augmented insulin secretion is
a predictable result of GH administration to normal subjects. Thus, GH and
insulin are mutually stimulatory although the relationship depends on
their opposing effect on plasma glucose, apparently the ultimate regulator
of the secretion of both hormones.
Whereas GH and insulin respond in
opposite ways to glucose levels, aminoacidemia is stimulatory to the release
of both polypeptides, presumably
through a mechanism not involving
glucose.
Growth failure in hypothyroidism is

in part due to GH failure. Similar
impaired secretion has not been demonstrated for the other pituitary hormones
in myxedema, and TSH is predictably
elevated. Thyroid hormone corrects the
impaired GH release. GH administration modifies plasma binding of the
thyroid hormone and a fall in PBI may
not necessarily reflect a decrease in
TSH secretion. Impaired thyroid secretion as a result of GH action, if proved
to be a physiologic fact, has no obvious
biologic utility since thyroid hormone
is required for optimal growth.
There is litde evidence that interaction between GH and ACTH, vasopressin, the catecholamines, the glucocorticoids and glucagon are significant
in everyday life. However, in conditions of physiologic stress in which
ACTH and the catecholamines are
liberated, subsequent release of GH
provides a reparative, anabolic or anticatabolic function. The reported GH
stimulatory effects of ACTH and of
the a-receptors of the sympathetic
nervous system offer a mechanism for
this reaction. Inasmuch as augmented
GH levels are not sustained in stress
states, the protective function of the
hormone has limited significance.
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